Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952089 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
A Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT05952089: Completed Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by Bristol-Myers Squibb.
NCT05952089 is a Phase 1 study of Heart Failure With Reduced Ejection Fraction that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 13 participants, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05952089, a Phase 1 study of Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Danicamtiv
Study Locations (5)
Florida
- Holy Cross Hospital - Fort Lauderdale
- Nature Coast Clinical Research - Inverness
- Jacksonville Center For Clinical Research - Jacksonville
Kentucky
- Research Integrity LLC - Owensboro
Maryland
- Sinai Hospital Of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 1 |
What the finished NCT05952089 record still lists
NCT05952089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.
NCT05952089 lists 5 locations in 3 states (Florida, Kentucky, Maryland).
Frequently Asked Questions
What is clinical trial NCT05952089 about?
NCT05952089 is a clinical study titled "A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure". The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT05952089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-08-17. Estimated completion is 2024-03-19.
What conditions does trial NCT05952089 study?
This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT05952089?
The interventions under investigation include: Midazolam (DRUG), Danicamtiv (DRUG).
Who is sponsoring clinical trial NCT05952089?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952089 being conducted?
This trial has 5 study locations across Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Reduced Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05952089's enrollment target sits among peer trials
13 27th of 27 higher than 1 of 27 other Heart Failure With Reduced Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Reduced Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
RECRUITING · Phase 1
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction
RECRUITING · NA
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI